Primary mediastinal large B-cell lymphoma classification: Difference between revisions

Jump to navigation Jump to search
Newer edit →
VisualWikitext
Created page with "__NOTOC__ {{Primary mediastinal large B-cell lymphoma classification}} {{CMG}}; {{AE}} ==Overview== There is no established system for the classification of [disease name]...."
 
Line 4: Line 4:
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}  
==Overview==
==Overview==
There is no established system for the classification of [disease name].
There is no established system for the classification of primary mediastinal large B-cell lymphoma. However it was designated as a separate disorder in 2001 by World health organization. There are different stages of primary mediastinal large B-cell lymphoma, depending on the metastatic stage of disease.  


OR
==Classification==
Primary mediastinal B-cell lymphoma was recognized as a sub type of diffuse large B-cell lymphoma since the 1994 in Revised European American Lymphoma Classification.<ref name="pmid8068936">{{cite journal |vauthors=Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC |title=A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group |journal=Blood |volume=84 |issue=5 |pages=1361–92 |date=September 1994 |pmid=8068936 |doi= |url=}}</ref>
* It has been regarded as a unique clinical and biological entity since the 2001 according to World Health Organization classification.<ref name="pmid27399089">{{cite journal |vauthors=Liu PP, Wang KF, Xia Y, Bi XW, Sun P, Wang Y, Li ZM, Jiang WQ |title=Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis |journal=Medicine (Baltimore) |volume=95 |issue=27 |pages=e4054 |date=July 2016 |pmid=27399089 |pmc=5058818 |doi=10.1097/MD.0000000000004054 |url=}}</ref>


[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
=Stages of Primary mediastinal large B-cell lymphoma=


OR
* Staging for primary mediastinal large B-cell lymphoma is provided in the following table:<ref>{{Cite journal| doi = 10.1200/JCO.2013.54.8800| issn = 1527-7755| volume = 32| issue = 27| pages = 3059–3068| last1 = Cheson| first1 = Bruce D.| last2 = Fisher| first2 = Richard I.| last3 = Barrington| first3 = Sally F.| last4 = Cavalli| first4 = Franco| last5 = Schwartz| first5 = Lawrence H.| last6 = Zucca| first6 = Emanuele| last7 = Lister| first7 = T. Andrew| last8 = Alliance, Australasian Leukaemia and Lymphoma Group| last9 = Eastern Cooperative Oncology Group| last10 = European Mantle Cell Lymphoma Consortium| last11 = Italian Lymphoma Foundation| last12 = European Organisation for Research| last13 = Treatment of Cancer/Dutch Hemato-Oncology Group| last14 = Grupo Español de Médula Ósea| last15 = German High-Grade Lymphoma Study Group| last16 = German Hodgkin's Study Group| last17 = Japanese Lymphorra Study Group| last18 = Lymphoma Study Association| last19 = NCIC Clinical Trials Group| last20 = Nordic Lymphoma Study Group| last21 = Southwest Oncology Group| last22 = United Kingdom National Cancer Research Institute| title = Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification| journal = Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology| date = 2014-09-20| pmid = 25113753}}</ref>
 
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3].
|+ '''Revised staging system for primary nodal lymphomas (Lugano classification)'''
[Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
! style="background: #4479BA; color:#FFF;" | Stage
 
! style="background: #4479BA; color:#FFF;" | Involvement
OR
! style="background: #4479BA; color:#FFF;" | Extranodal (E) status
 
|-
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
| colspan="3" style="padding: 5px 5px; background: #DCDCDC;" | '''Limited'''
 
|-
OR
| style="padding: 5px 5px; background: #F5F5F5;" | Stage I
 
| style="padding: 5px 5px; background: #F5F5F5;" | One node or a group of adjacent nodes
If the staging system involves specific and characteristic findings and features:
| style="padding: 5px 5px; background: #F5F5F5;" | Single extranodal lesions without nodal involvement
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
|-
 
| style="padding: 5px 5px; background: #F5F5F5;" | Stage II
OR
| style="padding: 5px 5px; background: #F5F5F5;" | Two or more nodal groups on the same side of the diaphragm
 
| style="padding: 5px 5px; background: #F5F5F5;" | Stage I or II by nodal extent with limited contiguous extranodal involvement
The staging of [malignancy name] is based on the [staging system].
|-
 
| style="padding: 5px 5px; background: #F5F5F5;" | Stage II bulky
OR
| style="padding: 5px 5px; background: #F5F5F5;" | II as above with "bulky" disease
 
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable
There is no established system for the staging of [malignancy name].
|-
| colspan="3" style="padding: 5px 5px; background: #DCDCDC;" | '''Advanced'''
|-
| style="padding: 5px 5px; background: #F5F5F5;" | Stage III
| style="padding: 5px 5px; background: #F5F5F5;" | Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable
|-
| style="padding: 5px 5px; background: #F5F5F5;" | Stage IV
| style="padding: 5px 5px; background: #F5F5F5;" | Additional noncontiguous extralymphatic involvement
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable
|}


==Classification==
==Classification==

Revision as of 16:50, 2 January 2019

Template:Primary mediastinal large B-cell lymphoma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no established system for the classification of primary mediastinal large B-cell lymphoma. However it was designated as a separate disorder in 2001 by World health organization. There are different stages of primary mediastinal large B-cell lymphoma, depending on the metastatic stage of disease.

Classification

Primary mediastinal B-cell lymphoma was recognized as a sub type of diffuse large B-cell lymphoma since the 1994 in Revised European American Lymphoma Classification.[1]

  • It has been regarded as a unique clinical and biological entity since the 2001 according to World Health Organization classification.[2]

Stages of Primary mediastinal large B-cell lymphoma

  • Staging for primary mediastinal large B-cell lymphoma is provided in the following table:[3]
Revised staging system for primary nodal lymphomas (Lugano classification)
Stage Involvement Extranodal (E) status
Limited
Stage I One node or a group of adjacent nodes Single extranodal lesions without nodal involvement
Stage II Two or more nodal groups on the same side of the diaphragm Stage I or II by nodal extent with limited contiguous extranodal involvement
Stage II bulky II as above with "bulky" disease Not applicable
Advanced
Stage III Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement Not applicable
Stage IV Additional noncontiguous extralymphatic involvement Not applicable

Classification

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups:

  • [Group1]
  • [Group2]
  • [Group3]
  • [Group4]

OR

[Disease name] may be classified into [large number > 6] subtypes based on:

  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

[Disease name] may be classified into several subtypes based on:

  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features:

According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

References

  1. ↑ Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC (September 1994). "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group". Blood. 84 (5): 1361–92. PMID 8068936.
  2. ↑ Liu PP, Wang KF, Xia Y, Bi XW, Sun P, Wang Y, Li ZM, Jiang WQ (July 2016). "Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis". Medicine (Baltimore). 95 (27): e4054. doi:10.1097/MD.0000000000004054. PMC 5058818. PMID 27399089.
  3. ↑ Cheson, Bruce D.; Fisher, Richard I.; Barrington, Sally F.; Cavalli, Franco; Schwartz, Lawrence H.; Zucca, Emanuele; Lister, T. Andrew; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute (2014-09-20). "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 32 (27): 3059–3068. doi:10.1200/JCO.2013.54.8800. ISSN 1527-7755. PMID 25113753.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Primary_mediastinal_large_B-cell_lymphoma_classification&oldid=1513471"